RegulatoryCompany release

Larimar completes BLA submission for nomlabofusp in Friedreich's ataxia, seeking accelerated approval

🇺🇸 Larimar Therapeutics, Inc. (LRMR) · Mon 16 Nov 2026

The US biotech is relying on skin frataxin as a novel surrogate endpoint and expects the FDA's filing decision in early 2027, with approval targeted for mid-2027.

Larimar Therapeutics has completed its rolling Biologics License Application (BLA) to the US Food and Drug Administration for nomlabofusp, seeking accelerated approval in adults and children with Friedreich's ataxia. The company disclosed the milestone on 16 November 2026 alongside its third-quarter 2026 update.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Larimar Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Larimar Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →